Nuvation Bio (NUVB) Current Assets (2020 - 2026)

Nuvation Bio (NUVB) has reported Current Assets for 7 consecutive years, with $591.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets rose 24.38% year-over-year to $591.5 million; the TTM figure through Mar 2026 stood at $591.5 million (up 24.38% YoY), while the FY2025 annual figure was $571.5 million, up 8.6% from the prior year.
• Current Assets improved to $591.5 million in Q1 2026 per NUVB's latest filing, from $571.5 million in the prior quarter.
• Across five years, Current Assets topped out at $748.0 million in Q1 2022 and bottomed at $475.6 million in Q1 2025.
• Historically, Current Assets has averaged $615.8 million across 5 years, with a median of $616.4 million in 2023.
• Annual changes were most pronounced in 2025 — Current Assets decreased 21.79% — and 2026, when it advanced 24.38%.
• Nuvation Bio's Current Assets stood at $667.3 million in 2022, then retreated by 7.63% to $616.4 million in 2023, then slipped by 14.63% to $526.3 million in 2024, then advanced by 8.6% to $571.5 million in 2025, then grew by 3.5% to $591.5 million in 2026.
• Business Quant data shows NUVB's Current Assets at $591.5 million in Q1 2026, $571.5 million in Q4 2025, and $577.5 million in Q3 2025.